Summary:
This clinical research study will be a multicenter, open-label, flexible-dose,12 month study in adults with Attention Deficit Hyperactivity Disorder as diagnosed by DSM.IV-TR who have ADHD symptoms for at least 6 months.The study will include 3 periods: a 1-3 week screening period,followed by a 12 month period of open label treatment, followed by a 2 week safety follow-up period.